Prostate high dose-rate brachytherapy as monotherapy for prostate cancer: Late toxicity and patient reported outcomes from a randomized phase II clinical trial-Reference-Cited by-同舟云学术

Prostate high dose-rate brachytherapy as monotherapy for prostate cancer: Late toxicity and patient reported outcomes from a randomized phase II clinical trial

Published:2021-03 Issue: Volume:156 Page:160-165
ISSN:0167-8140
Container-title:Radiotherapy and Oncology
language:en
Short-container-title:Radiotherapy and Oncology

Author:

Corkum Mark,Loblaw Andrew^ORCID,Hasan Yaser,Chung Hans T.,Tseng Chia-Lin^ORCID,McGuffin Merrylee,Cheung Patrick,Szumacher Ewa,Liu Stanley^ORCID,Chu William^ORCID,Zhang Liying^ORCID,Mamedov Alexandre^ORCID,Morton Gerard^ORCID

Funder

Canadian Association of Radiation Oncology

Publisher

Elsevier BV

Subject

Radiology, Nuclear Medicine and imaging,Oncology,Hematology

Reference37 articles.

1. High dose-rate brachytherapy in the treatment of prostate cancer;Mendez;Transl. Androl. Urol.,2018

2. The evolution of brachytherapy for prostate cancer;Zaorsky;Nat Rev Urol,2017

3. Results of 15 Gy HDR-BT boost plus EBRT in intermediate-risk prostate cancer: Analysis of over 500 patients;Martell;Radiother Oncol,2019

4. High-dose-rate brachytherapy boost for prostate cancer: rationale and technique;Morton;J Contemp Brachytherapy,2014

5. Long-term toxicity and health-related quality of life after single-fraction high dose rate brachytherapy boost and hypofractionated external beam radiotherapy for intermediate-risk prostate cancer;Shahid;Clinical Oncology,2017

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prostate high dose-rate brachytherapy as monotherapy for low and intermediate-risk prostate cancer: Efficacy results from a randomized phase II clinical trial of one fraction of 19 Gy or two fractions of 13.5 Gy: A 9-year update;Radiotherapy and Oncology;2024-09

2. Radiotherapy in localized prostate cancer: a multicenter analysis evaluating tumor control and late toxicity after brachytherapy and external beam radiotherapy in 1293 patients;Strahlentherapie und Onkologie;2024-03-15

3. Comment to “Dosimetric correlates of toxicities and quality of life following two-fraction stereotactic ablative radiotherapy (SABR) for prostate cancer”;Radiotherapy and Oncology;2023-12

4. Population‐based patient‐reported quality of life outcomes following low‐dose‐rate versus high‐dose‐rate brachytherapy monotherapy for low‐intermediate risk prostate cancer;Journal of Medical Imaging and Radiation Oncology;2023-10

5. Efficacy of focal high-dose-rate brachytherapy in the treatment of patients diagnosed with low or favourable intermediate-risk prostate cancer—a protocol for a randomised controlled trial;BMJ Open;2023-05